Peptide Half-Life and Clearance: What the Literature Reports

What "half-life" means in the peptide literature

In pharmacokinetics, half-life (t½) describes the time required for the plasma concentration of a compound to fall by half once distribution is complete. It is a property of the elimination curve, not a measure of how long a biological effect lasts. Because each successive half-life removes half of what remains, roughly 94 to 97% of a single administered amount has been eliminated after four to five half-lives, which is why pharmacologists describe washout in multiples of t½ rather than in fixed hours.

Several other parameters appear alongside half-life in the peptide literature, and confusing them is the most common source of misunderstanding:

• T_max - the time to peak plasma concentration after administration.
• AUC - total exposure over time, used to compare formulations and routes.
• Clearance - the volume of plasma cleared of the compound per unit time, driven by proteolysis, renal filtration and receptor-mediated uptake.
• Steady state - the plateau reached with repeated administration, arrived at after approximately four to five half-lives.
• Duration of action - a pharmacodynamic measure that may be shorter or considerably longer than plasma exposure.

Why many native peptides are cleared within minutes

Endogenous peptides are built to be short-lived signals. A 2018 review in Nature Reviews Endocrinology described native glucagon-like peptide 1 as being rapidly inactivated by dipeptidyl peptidase 4 and cleared so quickly that only a small fraction of secreted hormone reaches its target receptors intact, giving it a circulating half-life of a few minutes (PMID 29728598). Ubiquitous peptidases in plasma, endothelium, liver and kidney, together with glomerular filtration of small unbound peptides, mean that an unmodified peptide sequence is generally a poor candidate for sustained exposure.

Reported half-lives: from minutes to about a week

The table below summarises what the cited studies and reviews reported. The ranges are properties of the specific molecules and species studied, not of "peptides" as a category.

A 2024 systematic review of semaglutide pharmacokinetics reported a terminal half-life of approximately one week and described accumulation to steady state over roughly four to five weeks of once-weekly administration (PMID 38952487). A 2025 comprehensive review of the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist reported half-lives ranging from hours for short-acting agents to days for once-weekly agents, and noted that because these molecules are catabolised by proteases rather than metabolised by cytochrome P450 enzymes, their direct interaction potential is low, with delayed gastric emptying the more relevant mechanism for co-administered oral drugs (PMID 40330819).

Molecular design that slows clearance

Most of the difference between a minutes-long and a week-long half-life comes from deliberate engineering. Researchers have used several recurring strategies, and the verified literature illustrates each.

Albumin binding

A 2022 study in Molecular Pharmaceutics reported that a "human and mouse cross-reactive" albumin-binding helix-loop-helix peptide tag prolonged the bioactivity of therapeutic proteins by tethering them to circulating albumin (PMID 35635006). A 2024 report in ACS Pharmacology & Translational Science applied a related principle to a vasoactive peptide, describing a 1,18-octadecanedioic acid-terlipressin conjugate as long-circulating compared with the unmodified peptide (PMID 38751631). The 2024 semaglutide review similarly attributed the analogue's extended exposure to albumin binding together with resistance to enzymatic degradation (PMID 38952487).

Protease resistance and route

Sequence modifications that block dipeptidyl peptidase 4 cleavage address the mechanism identified for native GLP-1 (PMID 29728598). Route of administration matters independently: a 2025 analysis in Dermatology and Therapy described the translational pharmacokinetics of icotrokinra, an orally administered targeted peptide that selectively blocks the interleukin-23 receptor, using cross-species data and modelling to project human exposure for an oral peptide (PMID 40629250).

How long peptides act compared with how long they are measurable

Plasma concentration is a proxy, not the effect itself. Several of the cited studies measured pharmacodynamics separately for exactly this reason. A 2023 paper in the International Journal of Molecular Sciences assessed the pharmacokinetics, disposition and duration of action of the tumour-targeting peptide CEND-1 as three distinct questions, rather than inferring the duration of effect from plasma exposure alone (PMID 36982773).

The same approach appears in first-in-human work on hepcidin mimetics. A 2024 double-blind first-in-human study in European Journal of Haematology evaluated the pharmacokinetics, pharmacodynamics and tolerability of an aqueous formulation of rusfertide in healthy volunteers, tracking iron-related pharmacodynamic markers alongside plasma concentrations (PMID 38785334). A companion 2024 report in Drugs in R&D characterised the pharmacokinetics and pharmacodynamics of a lyophilised powder formulation of the same hepcidin mimetic after subcutaneous administration in healthy volunteers (PMID 39546273). In both designs, the pharmacodynamic time course was measured rather than predicted from half-life.

Three general patterns are visible across such studies: effects can outlast measurable drug when a receptor event triggers a slower downstream process; effects can end while drug is still detectable when concentrations fall below the threshold required for receptor occupancy; and effects can accumulate over weeks when repeated administration of a long half-life compound builds toward steady state, as described for semaglutide (PMID 38952487).

Clearance routes described in the literature

Peptides are generally broken down to amino acids and small fragments rather than excreted intact. The 2025 pharmacokinetic and interaction review described proteolytic catabolism with renal and hepatic contributions as the dominant elimination pathway for approved incretin-based peptides, contrasting this with small-molecule hepatic metabolism (PMID 40330819). For endogenous fragments, the 2005 review of NT-proBNP described how production and clearance together determine the circulating concentration that laboratories measure, with the N-terminal fragment persisting longer than the active hormone (PMID 15948107). Molecular size, charge, albumin binding and renal function therefore all shift measured clearance.

Tolerability in Pharmacokinetic Studies: What Studies Report

Early-phase pharmacokinetic studies report tolerability alongside exposure, although they are not designed or powered to establish safety profiles. The 2024 double-blind first-in-human study of an aqueous rusfertide formulation in healthy volunteers reported tolerability as a co-primary consideration with pharmacokinetics and pharmacodynamics, with injection-site reactions among the observations described for the subcutaneous route (PMID 38785334). The subsequent lyophilised-powder study likewise assessed the hepcidin mimetic's safety in healthy volunteers in parallel with its pharmacokinetics and pharmacodynamics (PMID 39546273). For approved incretin-based agents, the 2025 interaction review emphasised gastric emptying effects as a mechanism relevant to co-administered oral medicines (PMID 40330819).

Why half-life figures do not transfer between contexts

Reported values are conditional on the study that produced them. Species differ: the semaglutide brain distribution work was conducted in rats (PMID 36989942), while the systematic review synthesised clinical data (PMID 38952487). Formulation differs: the two rusfertide studies examined an aqueous solution and a lyophilised powder respectively (PMID 38785334, PMID 39546273). Route differs, as the oral peptide modelling work illustrates (PMID 40629250). Renal function, body weight, antidrug antibodies and assay selectivity add further variation, and many compounds discussed in peptide forums have no published human pharmacokinetic data at all. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision or medication question.

References

• Clinical Pharmacokinetics of Semaglutide: A Systematic Review (Drug Design, Development and Therapy, 2024)
• Glucagon-like peptide 1 in health and disease (Nature Reviews Endocrinology, 2018)
• A Comprehensive Review on the Pharmacokinetics and Drug-Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist (Drug Design, Development and Therapy, 2025)
• Translational Pharmacokinetics of Icotrokinra, a Targeted Oral Peptide that Selectively Blocks Interleukin-23 Receptor and Inhibits Signaling (Dermatology and Therapy, 2025)
• NT-ProBNP: the mechanism behind the marker (Journal of Cardiac Failure, 2005)
• Novel LC-MS/MS analysis of the GLP-1 analog semaglutide with its application to pharmacokinetics and brain distribution studies in rats (Journal of Chromatography B, 2023)
• Pharmacokinetics, pharmacodynamics, and tolerability of an aqueous formulation of rusfertide (PTG-300), a hepcidin mimetic, in healthy volunteers: A double-blind first-in-human study (European Journal of Haematology, 2024)
• A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS (Drug Testing and Analysis, 2019)
• Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1 (International Journal of Molecular Sciences, 2023)
• Long-Circulating Vasoactive 1,18-Octadecanedioic Acid-Terlipressin Conjugate (ACS Pharmacology & Translational Science, 2024)
• "Human and Mouse Cross-Reactive" Albumin-Binding Helix-Loop-Helix Peptide Tag for Prolonged Bioactivity of Therapeutic Proteins (Molecular Pharmaceutics, 2022)
• Pharmacokinetics and Pharmacodynamics of Rusfertide, a Hepcidin Mimetic, Following Subcutaneous Administration of a Lyophilized Powder Formulation in Healthy Volunteers (Drugs in R&D, 2024)